Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program
K C Allen Chan, Emily C W Hung, John K S Woo, Paul K S Chan, Sing-Fai Leung, Franco P T Lai, Anita S M Cheng, Sze Wan Yeung, Yin Wah Chan, Teresa K C Tsui, Jeffrey S S Kwok, Ann D King, Anthony T C Chan, Andrew C van Hasselt, Y M Dennis Lo, K C Allen Chan, Emily C W Hung, John K S Woo, Paul K S Chan, Sing-Fai Leung, Franco P T Lai, Anita S M Cheng, Sze Wan Yeung, Yin Wah Chan, Teresa K C Tsui, Jeffrey S S Kwok, Ann D King, Anthony T C Chan, Andrew C van Hasselt, Y M Dennis Lo
Abstract
Background: Nasopharyngeal carcinoma (NPC) is prevalent in Southeast Asia. Over the last decade, plasma Epstein-Barr virus (EBV) DNA has been developed as a tumor marker for NPC. In this study, the authors investigated whether plasma EBV DNA analysis is useful for NPC surveillance.
Methods: In total, 1318 volunteers ages 40 to 60 years were prospectively recruited. Plasma EBV DNA and serology for viral capsid antigen immunoglobulin A (IgA) were measured. Participants who had detectable plasma EBV DNA or positive IgA serology underwent nasal endoscopic examination and a follow-up plasma EBV DNA analysis in approximately 2 weeks. All participants were followed for 2 years to record the development of NPC.
Results: Three individuals with NPC were identified at enrolment. All of them were positive for EBV DNA and remained positive in follow-up analysis. Only 1 of those patients was positive for EBV serology. In 1 patient who had NPC with a small tumor confined to the mucosa, the tumor was not detectable on endoscopic examination. Because of a 2-fold increase in plasma EBV DNA on the follow-up analysis, that patient underwent magnetic resonance imaging, which revealed the tumor. Among the participants who did not have NPC but had initially positive plasma EBV DNA results, approximately 66% had negative EBV DNA results after a median of 2 weeks.
Conclusions: Plasma EBV DNA analysis proved useful for detecting early NPC in individuals without a clinical suspicion of NPC. Repeating the test in those who had initially positive results differentiated those with NPC from those who had false-positive results. Cancer 2013. © 2013 American Cancer Society.
Copyright © 2013 American Cancer Society.
Source: PubMed